Corrigendum to “An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human non-hematopoietic tumor cells” [Int Immunopharmacol 2008 Dec 20;8(13–14):1813–20](S1567576908002683)(10.1016/j.intimp.2008.08.022);An anti-transferrin receptor antibody enhanced the growth inhibitory effects of chemotherapeutic drugs on human non-hematopoietic tumor cells

International Immunopharmacology

Volumn 8, Issue 13-14, 2008, Pages 1813-1820

  Shen, Xin ^a,b   Zhu, Hui fen ^a   He, Feng rong ^a   Xing, Wei ^a   Li, Li ^a   Liu, Jing ^a   Yang, Juan ^a   Pan, Xing fei ^a   Lei, Ping ^a   Wang, Zhi hua ^c   Shen, Guan xin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Chemoimmunotherapy; Chemotherapeutic drug; Monoclonal antibody; Non hematopoietic tumor cells; Transferrin receptor

Indexed keywords

7 AMINODACTINOMYCIN; ANTINEOPLASTIC AGENT; BETA ACTIN; DOXORUBICIN; FLUOROURACIL; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7579; RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR CELL;

EID: 55249095619     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.12.015     Document Type: Erratum

References (23)

1. Jone D.T., Trowbridge I.S., and Harris A.L. Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res 66 (2006) 2749-2756
2. Peng J.L., Wu S., Zhao X.P., Wang M., Li W.H., Shen X., et al. Downregulation of transferrin receptor surface expression by intracellular antibody. Biochem Biophys Res Commun 354 (2007) 864-871
3. Ng P.P., Dela Cruz J.S., Sorour D.N., Stinebaugh J.M., Shin S.U., Shin D.S., et al. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc Natl Acad Sci U S A 99 (2002) 10706-10711
4. Trowbridge I.S., and Domingo D.L. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature 294 (1981) 171-173
5. Domingo D.L., and Trowbridge I.S. Transferrin receptor as a target for antibody-drug conjugates. Methods Enzymol 112 (1985) 238-247
6. Ye Q., Wang S., Wang Z.H., Zhu H.F., Lei P., Liu L.J., et al. The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor. Cancer Immunol Immunother 55 (2006) 1111-1121
7. Brooks D., Taylor C., Dos Santos B., Linden H., Houghton A., Hecht T.T., et al. Phase Ia trial of murine immunoglobulin an antitransferrin receptor antibody 42/6. Clin Cancer Res 11 (1995) 1259-1265
8. Moura I.C., Lepelletier Y., Arnulf B., England P., Baude C., Beaumont C., et al. A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients. Blood 103 (2004) 1838-1845
9. Lepelletier Y., Camara-Clayette V., Jin H., Hermant A., Coulon S., Dussiot M., et al. Prevention of mantle lymphoma tumor establishment by routing transferrin receptor toward lysosomal compartments. Cancer Res 67 (2007) 1145-1154
10. Ng P.P., Helguera G., Daniels T.R., Lomas S.Z., Rodriguez J.A., Schiller G., et al. Molecular events contributing to cell death in malignant human hematopoietic cells elicited by an IgG3-avidin fusion protein targeting the transferrin receptor. Blood 108 (2006) 2745-2754
11. Kondo K., Noguchi M., Mukai K., Matsuno Y., Sato Y., Shimosato Y., et al. Transferrin receptor expression in adenocarcinoma of the lung as a histopathologic indicator of prognosis. Chest 97 (1990) 1367-1371
12. Seymour G.J., Walsh M.D., Lavin M.F., Strutton G., and Gardiner R.A. Transferrin receptor expression by human bladder transitional cell carcinomas. Urol Res 15 (1987) 341-344
13. Yang D.C., Wang F., Elliott R.L., and Head J.F. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer. Anti-cancer Res 21 (2001) 541-549
14. Ryschich E., Huszty G., Knaebel H.P., Hartel M., Buchler M.W., and Schmidt J. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas. Eur J Cancer 40 (2004) 1418-1422
15. Chou T.C., and Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 4 (1983) 450-454
16. Kemp J.D., Thorson J.A., Mcalmont T.H., Horowitz M., Cowdery J.S., and Ballas Z.K. Role of the transferring receptor in lymphocyte growth: a rat IgG monoclonal antibody against the murine transferrin receptor produces highly selective inhibition of T and B cell activation protocols. J Immunol 138 (1987) 2422-2426
17. Trowbridge I.S., and Lopez F. Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cells growth in vitro. Proc Natl Acad Sci U S A 79 (1982) 1175-1179
18. Lesley J.F., and Schulte R.J. Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies. Mol Cell Biol 5 (1985) 1814-1821
19. Lesley J., Schulte R., and Woods J. Modulation of transferrin receptor expression and function by anti-transferrin receptor antibodies and antibody fragments. Exp Cell Res 182 (1989) 215-233
20. Pegram M., Hsu S., Lewis G., Pietras R., Beryt M., Sliwkowski M., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 (1999) 2241-2251
21. Xu X., Persson H.L., and Richardson D.R. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 68 (2005) 261-271
22. Kaiserova H., den Hartog G.J., Simunek T., Schroterova L., Kvasnickova E., and Bast A. Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin. Br J Pharmacol 149 (2006) 920-930
23. Wu X., and Hasinoff B.B. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anti-cancer Drugs 16 (2005) 93-99